Back to results
US 12,202,904 B2Granted
IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
AssigneeDana-Farber Cancer Institute, Inc.
InventorsHarvey Cantor, Hye-Jung Kim, Jessica M. Sido
Life of this patent
Estimating the term…
Abstract
Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12Rβ activity and/or IL-12Rβ expression.
Claims4
A method for inducing differentiation of a regulatory T (Treg) cell to an effector T (Teff) cell, comprising contacting the Treg cell with an agent that decreases IL-23R activity and does not decrease IL-12Rβ activity;
- wherein the agent comprises a human or humanized antibody derived from mouse monoclonal antibody 12B2B64.
Dependencies are inferred from the claim text.